AEON-WS Stock Price, News & Analysis

AEON Biopharma, Inc. (NYSE: AEON, AEON WS) is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics for serious medical conditions. The company's flagship product, ABP-450 (prabotulinumtoxinA) Injection, is a proprietary botulinum toxin complex designed to treat debilitating conditions such as episodic and chronic migraines, cervical dystonia, and gastroparesis. ABP-450 is the same botulinum toxin type-A complex marketed for cosmetic use under the name Jeuveau by Evolus and is manufactured by Daewoong in compliance with cGMP standards.

AEON recently completed a significant merger and business combination with Priveterra Acquisition Corp., resulting in the company's listing on the New York Stock Exchange American. The company has secured $125 million in funding, which includes approximately $50 million in committed financing from existing and new investors, ensuring a cash runway beyond the announcement of key clinical milestones in their ongoing Phase 2 studies.

In the realm of clinical development, AEON's pipeline is robust. Besides completing a Phase 2 study for episodic migraine, which showed promising results, the company is also conducting a Phase 2 study for chronic migraine. However, the initial topline results from the Phase 2 study for chronic migraine did not meet the primary endpoint, prompting AEON to undertake further analysis and strategic review.

AEON has a diverse late-stage clinical pipeline targeting multiple indications. This includes plans for a Phase 3 study of ABP-450 for cervical dystonia and a Phase 2 study for gastroparesis, both of which are poised to advance pending final approvals. Additionally, IND-enabling studies are planned for the treatment of PTSD, further showcasing AEON's commitment to addressing unmet medical needs.

The company's management team comprises industry veterans with extensive experience in biopharmaceutical development and commercialization. This team is led by CEO Marc Forth and Chairman Jost Fischer, who have guided AEON through pivotal milestones, including significant funding rounds and obtaining a key U.S. patent for the use of ABP-450 in treating migraines.

For more information on AEON Biopharma and their innovative therapeutic solutions, visit their official website at www.aeonbiopharma.com.